Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1839]
News [4199]
Articles [376]
Editorials [10]
Conferences [104]
elearning [29]
Breast cancer highlights from ASCO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...
Dr Zahi Mitri - OHSU Hospital, Portland, USA
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )
6 Jun 2019
Better education about breast cancer treatment in Africa
Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International...
Better education about breast cancer treatment in Africa ( Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International, Accra, Ghana )
5 Jun 2019
Genomic trends across the African Diaspora for breast cancer
Prof Melissa B Davis - Weill Cornell Medical College, New York, USA
Genomic trends across the African Diaspora for breast cancer ( Prof Melissa B Davis - Weill Cornell Medical College, New York, USA )
5 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Potential of PARP inhibitors for metastatic breast cancer
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
PARP inhibitors are a promising alternative to chemotherapy for patients with...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
Ribociclib and endocrine therapy improves survival for pre-menopausal women...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
Treating ovarian cancer patients with PARP inhibitors
Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA
Treating ovarian cancer patients with PARP inhibitors ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )
8 May 2019
PARP inhibitors and their side effects in solid tumour therapy
Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )
8 May 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation